Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:administeredBy |
oral
|
| gptkbp:approvalYear |
2021
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
L01EM05
|
| gptkbp:genericName |
gptkb:umbralisib
|
| https://www.w3.org/2000/01/rdf-schema#label |
Ukoniq
|
| gptkbp:manufacturer |
gptkb:TG_Therapeutics
|
| gptkbp:mechanismOfAction |
PI3K delta and CK1 epsilon inhibitor
|
| gptkbp:retired |
safety concerns
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
diarrhea
infections elevated liver enzymes neutropenia |
| gptkbp:usedFor |
treatment of follicular lymphoma
treatment of marginal zone lymphoma |
| gptkbp:withdrawn |
2022
yes |
| gptkbp:bfsParent |
gptkb:umbralisib
|
| gptkbp:bfsLayer |
6
|